# Domain Expert Evaluation: BACE1 Physiological Functions and Translational Risk
## 1. Hypotheses with Highest Translational Potential
### Hypothesis Ranking
| Rank | Hypothesis | Translational Priority | Rationale |
|------|-----------|----------------------|-----------|
| **1** | NRG1 Type III / Node of Ranvier | **High** | Clinical trial failures show cognitive worsening—directly implicates myelination/conduction mechanisms; explains why BACE inhibition worsens rather than helps cognition |
| **2** | Synaptic Function / Activity-Dependent Processing | **High** | BACE1 is activity-regulated; explains acute cognitive effects observed in trials (weeks to months); fits human safety data timeline |
| **3** | Neurovascular Coupling | **Moderate-High** | AD pathology includes vascular dysfunction; BACE1 expressed in endothelial cells; testable with existing imaging infrastructure |
### Rationale for Prioritization
The **lanabecestat** (NCT02972658) and **verubecestat** (EPOCH trial) failures are instructive: both showed dose-dependent **cognitive worsening** in treatment arms that emerged within 6-12 months. This is not a tumor-promotion or delayed toxicity—this is an **acute, on-target mechanism** affecting cognition. The NRG1/nodal hypothesis directly predicts this outcome through disrupted saltatory conduction, providing a mechanistic explanation for paradoxical clinical findings.
The Synaptic Function hypothesis (if presented) is equally high-priority because it addresses the activity-dependence of BACE1: neuronal activity increases BACE1 expression and trafficking to synapses, meaning inhibition would have **greatest effect during periods of highest demand**—exactly when cognitive performance is most needed.
---
## 2. Clinical Evidence, Safety, and Patient Population Fit
### Hypothesis 1: NRG1 Type III / Node of Ranvier
**Clinical Evidence (from BACE inhibitor trials):**
- Verubecestat EPOCH trial (PMID: 30256211): Significant worsening on ADAS-Cog11 and ADAS-Cog13 in mild-to-moderate AD at 18 months; effects emerged as early as 6 months
- Lanabecestat DAYBREAK trial (PMID: 31369549): Worsening of cognitive function and increased psychiatric adverse events led to termination
- These cognitive effects are **not explained by insufficient Aβ reduction**—they represent active toxicity
**Safety Considerations:**
- Current evidence suggests a **narrow therapeutic window**: sufficient Aβ reduction requires doses that produce cognitive toxicity
- The Trembler-like phenotype in BACE1-null mice (peripheral hypomyelination) has no direct human correlate but suggests developmental exposure would be catastrophic
- Adult exposure effects are more subtle but measurable (cognitive decline in trials)
**Patient Population Fit:**
- **Mild Cognitive Impairment due to AD** (pre-dementia): Rationale—earlier intervention may allow developmental compensation, fewer established degenerative changes; risk of nodal disruption may be more tolerable
- **Asymptomatic at-risk populations** (e.g., autosomal dominant AD, AρoE4 homozygotes): The prevention paradigm is compelling but *only if* safety is established in prodromal populations first
- **Moderate-severe AD**: Less appropriate—already compromised neural networks would be most vulnerable to conduction deficits
### Hypothesis 2: Synaptic Activity-Dependent Processing
**Clinical Evidence:**
- BACE1 expression increases with neuronal activity (PMID: 11739383, 15045088)
- BACE1 traffics to pre-synaptic terminals in an activity-dependent manner